Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
Nedosiran
open-in-new
<p>Nedosiran, sold under the brand name Rivfloza, is a <a href="/facts/Medication/h9mhwWP2">medication</a> used for the treatment of <a href="/facts/Primary_hyperoxaluria/uPChboAN">primary hyperoxaluria</a>. It is an <a href="/facts/Lactate_dehydrogenase_A/d4th5Clh">LDHA</a>-directed <a href="/facts/Small_interfering_RNA/891ytkD9">small interfering RNA</a> developed by Dicerna Pharmaceuticals. </p><p>The most common side effects include injection site reactions. </p><p>Nedosiran was approved for medical use in the United States in September 2023. The US <a href="/facts/Food_and_Drug_Administration/rCEnh9WB">Food and Drug Administration</a> (FDA) considers it to be a <a href="/facts/First-in-class_medication/ksvbEbS4">first-in-class medication</a>. </p>